Cannabis and Postpartum Depression
An evidence review of cannabis use for postpartum depression, lactation safety, and effective alternatives.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Some people hope cannabis will ease postpartum depression, sleep loss, or anxiety. But there are zero controlled trials supporting this use, while clear evidence shows THC transfers into breast milk and persists for weeks. Observational data suggests postpartum cannabis use correlates with worse mental health outcomes—though cause isn't proven. Standard treatments (SSRIs, therapy, newer neurosteroids) have decades of safety data and proven efficacy. Cannabis doesn't belong in the postpartum treatment conversation yet.
Not medical advice
This article is not medical advice. Postpartum depression is a serious condition that can escalate quickly. If you are experiencing PPD symptoms — persistent sadness, intrusive thoughts, inability to bond with your baby, or thoughts of harming yourself or your baby — contact your obstetrician, midwife, primary care doctor, or a perinatal mental health specialist. In the US, you can call or text the Maternal Mental Health Hotline at 1-833-852-6262 (1-833-TLC-MAMA), or the 988 Suicide & Crisis Lifeline. This article summarizes published evidence; it does not replace a clinician who knows your full history.
Plain-language summary
Postpartum depression (PPD) affects roughly 1 in 8 birthing people in the US [1]. Symptoms include persistent low mood, anxiety, sleep problems, guilt, and difficulty bonding with the infant. It is treatable — typically with therapy, SSRIs (like sertraline), and in severe cases brexanolone or zuranolone, newer neurosteroid drugs developed specifically for PPD [2].
Cannabis use during pregnancy and the postpartum period has risen sharply over the last decade [3]. Some people use it specifically hoping it will help mood, anxiety, or sleep. But there are essentially zero controlled trials of cannabis as a treatment for PPD. What we do have is observational data, which does not show benefit; it shows that THC transfers into breast milk [5][6], persists for weeks, and is detectable in infant urine and stool.
This doesn't mean cannabis 'causes' worse PPD — people struggling with depression may be more likely to self-medicate. But it does mean the case for cannabis as a treatment is completely unsupported, while the case against using it while breastfeeding is reasonably solid.
What works for postpartum depression (context)
For context, here is what the evidence actually supports for treating PPD:
- Cognitive behavioral therapy and interpersonal therapy Strong evidence — multiple RCTs and meta-analyses show meaningful symptom reduction [7].
- SSRIs, especially sertraline Strong evidence — sertraline has the most lactation safety data of any antidepressant and is generally first-line for breastfeeding parents [7].
- Brexanolone (Zulresso) and zuranolone (Zurzuvae) Strong evidence — FDA-approved specifically for PPD based on RCT data, though access and cost are real barriers [8].
- Exercise, peer support, and adequate sleep Weak / limited — helpful adjuncts.
Cannabis is not on this list because the controlled evidence does not exist.
What might work: cannabis mechanisms in PPD (low confidence)
Some mechanisms are biologically plausible but untested in postpartum depression:
- Short-term sleep onset Weak / limited — THC reduces sleep latency in some laboratory studies, but tolerance develops within days to weeks, REM sleep is suppressed, and discontinuation can worsen insomnia [9]. Sleep deprivation is a major driver of PPD; cannabis is not a reliable tool for it.
- Acute anxiety relief at low THC doses Weak / limited — small studies in non-postpartum populations suggest low-dose THC may reduce anxiety while higher doses increase it [10]. No PPD-specific trials exist. See THC Dose and Anxiety for more detail.
- CBD for anxiety Weak / limited — limited human data, mostly in non-postpartum populations, with unresolved questions about hepatic safety and unknown transfer into breast milk [11].
'Might work' means 'biologically plausible, not tested in this population.' That is much weaker than 'works.'
What doesn't work or has weak evidence
- Cannabis as a treatment for depression generally Weak / limited — systematic reviews find no clear antidepressant effect and some signal toward worsening depression with regular use [12]. See Cannabis and Depression for the broader picture.
- 'Indica strains for postpartum mood' No data — the indica/sativa distinction does not reliably predict effects. This is marketing folklore.
- Cannabis to 'help with bonding' Anecdote — no controlled data; the opposite effect is plausible if cognition or responsiveness is impaired.
- 'It's natural so it's safe while breastfeeding' Disputed — THC is highly lipophilic, concentrates in breast milk, and has been detected in infant urine and feces for up to 6 weeks after maternal use [5][6].
What we don't know
- Whether any specific cannabinoid (CBD, low-dose THC, CBG) has a therapeutic effect on PPD in controlled conditions. No RCTs exist.
- The long-term neurodevelopmental impact on infants of breast-milk THC exposure. Existing studies suggest possible motor and cognitive differences but are confounded by prenatal exposure and socioeconomic factors.
- Safe thresholds, if any, for cannabis use during lactation. Regulatory bodies currently recommend none [13].
- Whether CBD-only products with verified low THC carry meaningfully lower risk during lactation. Biologically plausible, but untested.
Comparison with standard treatments
| Treatment | Evidence for PPD | Lactation safety data | Access | Notes |
|---|---|---|---|---|
| Sertraline (SSRI) | Strong [7] | Strong; preferred SSRI | Wide, inexpensive | Decades of use |
| CBT / IPT | Strong [7] | N/A (no drug exposure) | Variable by region | Requires specialized training |
| Zuranolone (Zurzuvae) | Strong; FDA-approved | Limited but studied | Expensive, new | Oral, outpatient |
| Brexanolone (Zulresso) | Strong; FDA-approved [8] | Limited | Expensive, inpatient infusion | IV administration |
| Cannabis (THC) | None for PPD | Negative — THC transfers and persists in milk [5][6] | Variable by jurisdiction | No trials; observational signal toward harm |
| CBD | None for PPD | Unknown | Wide but unregulated | No lactation safety data |
The honest comparison: standard treatments have decades of safety data and proven efficacy. Cannabis has neither for postpartum depression.
Risks and harms
- Infant exposure via breast milk Strong evidence. THC is detectable in milk for days to weeks after maternal use; concentrations remain highest in mature milk [5][6]. The American Academy of Pediatrics and American College of Obstetricians and Gynecologists advise against cannabis use while breastfeeding [13].
- Possible neurodevelopmental effects on the infant Weak / limited. Observational data suggests associations with motor development differences; causation is not established, but the precautionary case is reasonable.
- Worsened depression with chronic use Weak / limited. Regular cannabis use is associated with higher rates of depression in observational studies [12]; however, the direction of causation is unclear.
- Impaired caregiving capacity Strong evidence. Acute intoxication affects reaction time and judgment — directly relevant when caring for a newborn requiring constant attention.
- Cannabis use disorder Weak / limited. Postpartum is a vulnerable period; escalation of use patterns can occur.
- Drug interactions with SSRIs, benzodiazepines, and other medications commonly prescribed for PPD. See Cannabis and Polypharmacy Risks.
If you are already using cannabis and struggling with PPD, the most useful thing is an honest conversation with a clinician — not shame, not silence. Stigma keeps people from getting effective treatment that exists.
Sources
- Government Centers for Disease Control and Prevention. Depression Among Women. Reproductive Health.
- Peer-reviewed Stewart DE, Vigod SN. Postpartum Depression: Pathophysiology, Treatment, and Emerging Therapeutics. Annual Review of Medicine. 2019;70:183-196.
- Peer-reviewed Volkow ND, Han B, Compton WM, McCance-Katz EF. Self-reported Medical and Nonmedical Cannabis Use Among Pregnant Women in the United States. JAMA. 2019;322(2):167-169.
- Peer-reviewed Bertrand KA, Hanan NJ, Honerkamp-Smith G, Best BM, Chambers CD. Marijuana Use by Breastfeeding Mothers and Cannabinoid Concentrations in Breast Milk. Pediatrics. 2018;142(3):e20181076.
- Peer-reviewed Baker T, Datta P, Rewers-Felkins K, Thompson H, Kallem RR, Hale TW. Transfer of Inhaled Cannabis Into Human Breast Milk. Obstetrics & Gynecology. 2018;131(5):783-788.
- Peer-reviewed Molyneaux E, Howard LM, McGeown HR, Karia AM, Trevillion K. Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews. 2014;(9):CD002018.
- Peer-reviewed Meltzer-Brody S, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. The Lancet. 2018;392(10152):1058-1070.
- Peer-reviewed Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Current Psychiatry Reports. 2017;19(4):23.
- Peer-reviewed Childs E, Lutz JA, de Wit H. Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress. Drug and Alcohol Dependence. 2017;177:136-144.
- Peer-reviewed Larsen C, Shahinas J. Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials. Journal of Clinical Medicine Research. 2020;12(3):129-141.
- Peer-reviewed Gobbi G, Atkin T, Zytynski T, et al. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood. JAMA Psychiatry. 2019;76(4):426-434.
- Peer-reviewed Grant KS, Petroff R, Isoherranen N, Stella N, Burbacher TM. Cannabis use during pregnancy: Pharmacokinetics and effects on child development. Pharmacology & Therapeutics. 2018;182:133-151.
- Peer-reviewed Forray A, Foster D. Substance Use in the Perinatal Period. Current Psychiatry Reports. 2015;17(11):91.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Depression — No randomized trials support cannabis for depression; heavy use correlates with worse mood...
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis and Psoriasis — What the evidence shows about cannabinoids for psoriasis plaques, itch, and joint pain.
- Cannabis Withdrawal and Sleep Disruption — Sleep disruption is a hallmark of cannabis withdrawal syndrome and typically resolves with...
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...